Dyne Therapeutics to Present at Upcoming Investor Conferences
Rhea-AI Summary
Dyne Therapeutics (Nasdaq: DYN) will present at multiple investor conferences in November–December 2025, featuring management fireside chats and live webcasts.
Scheduled events: Guggenheim Healthcare on Nov 10, 2025 at 10:00 a.m. ET (Boston); Stifel Healthcare on Nov 11, 2025 at 9:20 a.m. ET (New York); Jefferies Global Healthcare on Nov 17, 2025 at 3:00 p.m. GMT (10:00 a.m. ET, London); and Evercore Healthcare on Dec 2, 2025 at 9:35 a.m. ET (Coral Gables).
A live webcast will be available in the Investors & Media section at investors.dyne-tx.com, with replays accessible for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – DYN
In the Nov 3 session, DYN gained 6.78%, reflecting a notable positive market reaction. Argus tracked a peak move of +2.3% during that session. Argus tracked a trough of -10.2% from its starting point during tracking. Our momentum scanner triggered 34 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to present at the following upcoming investor conferences:
- Guggenheim 2nd Annual Healthcare Innovation Conference, fireside chat on Monday, November 10, 2025 at 10:00 a.m. ET in Boston, MA
- Stifel 2025 Healthcare Conference, fireside chat on Tuesday, November 11, 2025 at 9:20 a.m. ET in New York, NY
- Jefferies Global Healthcare Conference, fireside chat on Monday, November 17, 2025 at 3:00 p.m. GMT (10:00 a.m. ET) in London
- 8th Annual Evercore Healthcare Conference, fireside chat on Tuesday, December 2, 2025 at 9:35 a.m. ET in Coral Gables, FL
A live webcast of each presentation will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days.
About Dyne Therapeutics
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.
Contacts:
Investors
Mia Tobias
ir@dyne-tx.com
781-317-0353
Media
Stacy Nartker
snartker@dyne-tx.com
781-317-1938
